Research ExplorerPublicationsContribution of cystatin C- and creatinine-based definitions...

Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project

Standard

Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project. / Rothenbacher, Dietrich; Rehm, Martin; Iacoviello, Licia; Costanzo, Simona; Tunstall-Pedoe, Hugh; Belch, Jill J F; Söderberg, Stefan; Hultdin, Johan; Salomaa, Veikko; Jousilahti, Pekka; Linneberg, Allan; Sans, Susana; Padró, Teresa; Thorand, Barbara; Meisinger, Christa; Kee, Frank; McKnight, Amy Jayne; Palosaari, Tarja; Kuulasmaa, Kari; Waldeyer, Christoph; Zeller, Tanja; Blankenberg, Stefan; Koenig, Wolfgang; BiomarCaRE Consortium.

In: BMC MED, Vol. 18, No. 1, 300, 12.2020.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rothenbacher, D, Rehm, M, Iacoviello, L, Costanzo, S, Tunstall-Pedoe, H, Belch, JJF, Söderberg, S, Hultdin, J, Salomaa, V, Jousilahti, P, Linneberg, A, Sans, S, Padró, T, Thorand, B, Meisinger, C, Kee, F, McKnight, AJ, Palosaari, T, Kuulasmaa, K, Waldeyer, C, Zeller, T, Blankenberg, S, Koenig, W & BiomarCaRE Consortium 2020, 'Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project', BMC MED, vol. 18, no. 1, 300. https://doi.org/10.1186/s12916-020-01776-7

APA

Rothenbacher, D., Rehm, M., Iacoviello, L., Costanzo, S., Tunstall-Pedoe, H., Belch, J. J. F., Söderberg, S., Hultdin, J., Salomaa, V., Jousilahti, P., Linneberg, A., Sans, S., Padró, T., Thorand, B., Meisinger, C., Kee, F., McKnight, A. J., Palosaari, T., Kuulasmaa, K., ... BiomarCaRE Consortium (2020). Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project. BMC MED, 18(1), [300]. https://doi.org/10.1186/s12916-020-01776-7

Vancouver

Rothenbacher D, Rehm M, Iacoviello L, Costanzo S, Tunstall-Pedoe H, Belch JJF et al. Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project. BMC MED. 2020 Dec;18(1). 300. https://doi.org/10.1186/s12916-020-01776-7

Bibtex

@article{63bbef07d3444868baa0d45f2d94dc58,
title = "Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project",
abstract = "BACKGROUND: Chronic kidney disease has emerged as a strong cardiovascular risk factor, and in many current guidelines, it is already considered as a coronary heart disease (CHD) equivalent. Routinely, creatinine has been used as the main marker of renal function, but recently, cystatin C emerged as a more promising marker. The aim of this study was to assess the comparative cardiovascular and mortality risk of chronic kidney disease (CKD) using cystatin C-based and creatinine-based equations of the estimated glomerular filtration rate (eGFR) in participants of population-based and disease cohorts.METHODS: The present study has been conducted within the BiomarCaRE project, with harmonized data from 20 population-based cohorts (n = 76,954) from 6 European countries and 3 cardiovascular disease (CVD) cohorts (n = 4982) from Germany. Cox proportional hazards models were used to assess hazard ratios (HRs) for the various CKD definitions with adverse outcomes and mortality after adjustment for the Systematic COronary Risk Evaluation (SCORE) variables and study center. Main outcome measures were cardiovascular diseases, cardiovascular death, and all-cause mortality.RESULTS: The overall prevalence of CKD stage 3-5 by creatinine- and cystatin C-based eGFR, respectively, was 3.3% and 7.4% in the population-based cohorts and 13.9% and 14.4% in the disease cohorts. CKD was an important independent risk factor for subsequent CVD events and mortality. For example, in the population-based cohorts, the HR for CVD mortality was 1.72 (95% CI 1.53 to 1.92) with creatinine-based CKD and it was 2.14 (95% CI 1.90 to 2.40) based on cystatin-based CKD compared to participants without CKD. In general, the HRs were higher for cystatin C-based CKD compared to creatinine-based CKD, for all three outcomes and risk increased clearly below the conventional threshold for CKD, also in older adults. Net reclassification indices were larger for a cystatin-C based CKD definition. Differences in HRs (between the two CKD measures) in the disease cohorts were less pronounced than in the population-based cohorts.CONCLUSION: CKD is an important risk factor for subsequent CVD events and total mortality. However, point estimates of creatinine- and cystatin C-based CKD differed considerably between low- and high-risk populations. Especially in low-risk settings, the use of cystatin C-based CKD may result in more accurate risk estimates and have better prognostic value.",
keywords = "Cardiovascular Diseases/mortality, Coronary Disease/etiology, Creatinine/metabolism, Cystatin C/metabolism, Female, Heart Disease Risk Factors, Humans, Male, Middle Aged, Prognosis, Risk Assessment",
author = "Dietrich Rothenbacher and Martin Rehm and Licia Iacoviello and Simona Costanzo and Hugh Tunstall-Pedoe and Belch, {Jill J F} and Stefan S{\"o}derberg and Johan Hultdin and Veikko Salomaa and Pekka Jousilahti and Allan Linneberg and Susana Sans and Teresa Padr{\'o} and Barbara Thorand and Christa Meisinger and Frank Kee and McKnight, {Amy Jayne} and Tarja Palosaari and Kari Kuulasmaa and Christoph Waldeyer and Tanja Zeller and Stefan Blankenberg and Wolfgang Koenig and {BiomarCaRE Consortium}",
year = "2020",
month = dec,
doi = "10.1186/s12916-020-01776-7",
language = "English",
volume = "18",
journal = "BMC MED",
issn = "1741-7015",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project

AU - Rothenbacher, Dietrich

AU - Rehm, Martin

AU - Iacoviello, Licia

AU - Costanzo, Simona

AU - Tunstall-Pedoe, Hugh

AU - Belch, Jill J F

AU - Söderberg, Stefan

AU - Hultdin, Johan

AU - Salomaa, Veikko

AU - Jousilahti, Pekka

AU - Linneberg, Allan

AU - Sans, Susana

AU - Padró, Teresa

AU - Thorand, Barbara

AU - Meisinger, Christa

AU - Kee, Frank

AU - McKnight, Amy Jayne

AU - Palosaari, Tarja

AU - Kuulasmaa, Kari

AU - Waldeyer, Christoph

AU - Zeller, Tanja

AU - Blankenberg, Stefan

AU - Koenig, Wolfgang

AU - BiomarCaRE Consortium

PY - 2020/12

Y1 - 2020/12

N2 - BACKGROUND: Chronic kidney disease has emerged as a strong cardiovascular risk factor, and in many current guidelines, it is already considered as a coronary heart disease (CHD) equivalent. Routinely, creatinine has been used as the main marker of renal function, but recently, cystatin C emerged as a more promising marker. The aim of this study was to assess the comparative cardiovascular and mortality risk of chronic kidney disease (CKD) using cystatin C-based and creatinine-based equations of the estimated glomerular filtration rate (eGFR) in participants of population-based and disease cohorts.METHODS: The present study has been conducted within the BiomarCaRE project, with harmonized data from 20 population-based cohorts (n = 76,954) from 6 European countries and 3 cardiovascular disease (CVD) cohorts (n = 4982) from Germany. Cox proportional hazards models were used to assess hazard ratios (HRs) for the various CKD definitions with adverse outcomes and mortality after adjustment for the Systematic COronary Risk Evaluation (SCORE) variables and study center. Main outcome measures were cardiovascular diseases, cardiovascular death, and all-cause mortality.RESULTS: The overall prevalence of CKD stage 3-5 by creatinine- and cystatin C-based eGFR, respectively, was 3.3% and 7.4% in the population-based cohorts and 13.9% and 14.4% in the disease cohorts. CKD was an important independent risk factor for subsequent CVD events and mortality. For example, in the population-based cohorts, the HR for CVD mortality was 1.72 (95% CI 1.53 to 1.92) with creatinine-based CKD and it was 2.14 (95% CI 1.90 to 2.40) based on cystatin-based CKD compared to participants without CKD. In general, the HRs were higher for cystatin C-based CKD compared to creatinine-based CKD, for all three outcomes and risk increased clearly below the conventional threshold for CKD, also in older adults. Net reclassification indices were larger for a cystatin-C based CKD definition. Differences in HRs (between the two CKD measures) in the disease cohorts were less pronounced than in the population-based cohorts.CONCLUSION: CKD is an important risk factor for subsequent CVD events and total mortality. However, point estimates of creatinine- and cystatin C-based CKD differed considerably between low- and high-risk populations. Especially in low-risk settings, the use of cystatin C-based CKD may result in more accurate risk estimates and have better prognostic value.

AB - BACKGROUND: Chronic kidney disease has emerged as a strong cardiovascular risk factor, and in many current guidelines, it is already considered as a coronary heart disease (CHD) equivalent. Routinely, creatinine has been used as the main marker of renal function, but recently, cystatin C emerged as a more promising marker. The aim of this study was to assess the comparative cardiovascular and mortality risk of chronic kidney disease (CKD) using cystatin C-based and creatinine-based equations of the estimated glomerular filtration rate (eGFR) in participants of population-based and disease cohorts.METHODS: The present study has been conducted within the BiomarCaRE project, with harmonized data from 20 population-based cohorts (n = 76,954) from 6 European countries and 3 cardiovascular disease (CVD) cohorts (n = 4982) from Germany. Cox proportional hazards models were used to assess hazard ratios (HRs) for the various CKD definitions with adverse outcomes and mortality after adjustment for the Systematic COronary Risk Evaluation (SCORE) variables and study center. Main outcome measures were cardiovascular diseases, cardiovascular death, and all-cause mortality.RESULTS: The overall prevalence of CKD stage 3-5 by creatinine- and cystatin C-based eGFR, respectively, was 3.3% and 7.4% in the population-based cohorts and 13.9% and 14.4% in the disease cohorts. CKD was an important independent risk factor for subsequent CVD events and mortality. For example, in the population-based cohorts, the HR for CVD mortality was 1.72 (95% CI 1.53 to 1.92) with creatinine-based CKD and it was 2.14 (95% CI 1.90 to 2.40) based on cystatin-based CKD compared to participants without CKD. In general, the HRs were higher for cystatin C-based CKD compared to creatinine-based CKD, for all three outcomes and risk increased clearly below the conventional threshold for CKD, also in older adults. Net reclassification indices were larger for a cystatin-C based CKD definition. Differences in HRs (between the two CKD measures) in the disease cohorts were less pronounced than in the population-based cohorts.CONCLUSION: CKD is an important risk factor for subsequent CVD events and total mortality. However, point estimates of creatinine- and cystatin C-based CKD differed considerably between low- and high-risk populations. Especially in low-risk settings, the use of cystatin C-based CKD may result in more accurate risk estimates and have better prognostic value.

KW - Cardiovascular Diseases/mortality

KW - Coronary Disease/etiology

KW - Creatinine/metabolism

KW - Cystatin C/metabolism

KW - Female

KW - Heart Disease Risk Factors

KW - Humans

KW - Male

KW - Middle Aged

KW - Prognosis

KW - Risk Assessment

U2 - 10.1186/s12916-020-01776-7

DO - 10.1186/s12916-020-01776-7

M3 - SCORING: Journal article

C2 - 33161898

VL - 18

JO - BMC MED

JF - BMC MED

SN - 1741-7015

IS - 1

M1 - 300

ER -